Therapies and Technologies
Headline, Therapies and Technologies »
“Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma.”
The product is a graft of an expanded population o hematopoieticf stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted …
Company press release:
“MESOBLAST’S NEOFUSE STEM CELL PRODUCT SHOWS POSITIVE RESULTS
IN PHASE 2 LUMBAR SPINAL FUSION TRIAL”
The benefit will be eliminating the need for an autograft bone harvest and avoid the risks of this procedure, including pain, infection and blood loss.
www.mesoblast.com Melbourne, Australia
Improvement of engraftment of blood stem cells following ex vivo expansion in co-culture with mesenchymal stem cells.
Clinical results of study in 31 patients with hematologic cancers following transplantation of two cord blood units.
Cord Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture
Marcos de Lima et al. N Engl J Med. 2012 Dec 13;367(24):2305-15
About 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a mild positive response to the procedure.
Company website: http://www.precisionstemcell.com/index.cfm
Gulf Shores, Alabama
Principal Investigator: Dr. Jason R. Williams
Fate Therapeutics, Inc., announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancy.
“ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.”
Source: company press release -
Company website: http://www.fatetherapeutics.com
Therapies and Technologies »
FDA Approves DUCORD Product from Duke for Stem Cell Transplants
“DUCORD is approved for use in hematopoietic stem cell transplantation for patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.”
Duke, North Carolina, USA
“TiGenix enrolls first patients in pivotal Phase III trial
with lead product Cx601 in perianal fistulas
ADMIRE CD trial to enroll over 200 patients in 46 centers
across 8 countries.”
Press Release: http://www.tigenix.com/public/uploads/pdf/en/f4ffbd7471a4a24.76706543_120710_TiGenix_Press%20Release_Phase_III_Cx601_ENG.pdf?elq=7e9afdd9f0954178a69fff1065d0a977
Tigenix Belgium http://www.tigenix.com/
Regenerative medicine company Histogenics Corporation, announced today the presentation of intermediate term data supporting the clinical efficacy of the Company’s NeoCart Autologous Cartilage Tissue Implant (ACTI) for periods of up to five years with no evidence of severe treatment-related adverse events in patients with grade III chondral injury to the femur (cartilage damage in the knee).
NeoCart® is an implant grown ex vivo (outside the body) from the patient’s own cartilage cells.
NeoCart recently entered a Phase …
Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon
BMC Medicine 2012, 10:3 http://www.biomedcentral.com/1741-7015/10/3/abstract
“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them …